New pharmacological strategies for pain relief

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 253-280

  Dray, A ^a,b   Urban, L ^a  

^a Sandoz Institute for Medical Research   (United Kingdom)

^b Astra Pain Research Unit   (Canada)

Author keywords

analgesia; inflammation; nerve injury; nervous system; neurochemistry

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 3 (1H INDOL 3 YL) 1 [N (2 METHOXYBENZYL)ACETYLAMINO] 2 [N [2 [4 (1 PIPERIDINYL) 1 PIPERIDINYL]ACETYL]AMINO]PROPANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BRADYKININ ANTAGONIST; CAPSAICIN; CAPSAICIN DERIVATIVE; CAPSAZEPINE; DELTIBANT; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 7 DEXTRO PHENYLALANINE]; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; ICATIBANT; LANEPITANT; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NERVE GROWTH FACTOR; NOLPITANTIUM; NONSTEROID ANTIINFLAMMATORY AGENT; NPC 1672; NUVANIL; OLVANIL; OPIATE; PEPTIDE HORMONE ANTAGONIST; PURINERGIC RECEPTOR STIMULATING AGENT; RESINIFERATOXIN; RP 100893; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 69338; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE;

ANALGESIA; HUMAN; INFLAMMATION; NERVE INJURY; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW;

EID: 0029980957     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.36.040196.001345     Document Type: Review

References (194)

1. Wall PD, Melzack R. 1994. Textbook of Pain. Edinburgh: Churchill-Livingstone. 3rd ed.
2. von Korff M, Dworkin SF, Le Resche L. 1990. Graded chronic pain states: an epidemiological evaluation. Pain 40: 279-91
3. Dray A, Urban L, Dickenson AH. 1994. Pharmacology of chronic pain. Trends Pharmacol. Sci. 15:190-97
4. Levine JD, Fields HL, Basbaum AI. 1993. Peptides and the primary afferent nociceptor. J. Neurosci. 13:2273-86
5. Woolf CJ. 1994. The dorsal horn: state-dependent sensory processing and the generation of pain. See Ref. 1, pp. 101-12
6. McMahon SB, Lewin GR, Wall PD. 1993. Central hyperexcitability triggered by noxious inputs. Curr. Opin. Neurobiol. 3:602-10
7. Zieglgänsberger W, Tölle T. 1993. The pharmacology of pain signalling. Curr. Opin. Neurobiol. 3:611-18
8. Dray A. 1994. Tasting the inflammatory soup: the role of peripheral neurones. Pain Rev. 1:153-71
9. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. 1980. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284:271-74
10. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90:11693-97
11. Hla T, Nielson K. 1992. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA. 89:7389-98
12. 3H]iloprost. Neuroscience 65:493-503
13. Khasar SG, Ouseph AK, Chou B, Ho T, Green PG, Levine JD. 1995. Is there more than one prostaglandin E receptor subtype mediating hyperalgesia in the rat hindpaw? Neuroscience 64:1161-65
14. Crunkhorn P, Willis AL. 1971. Cutaneous reaction to intradermal prostaglandins. Br. J. Phamacol. 41:49-56
15. 2-induced activation and sensitization of articular mechanonociceptors. Neurosci. Lett. 124:5-8
16. 2 on rat neonatal cultured dorsal root ganglion cells. Br. J. Pharmacol. 105:133
17. 2 of bradykinin activation of embryonic rat sensory neurones. J. Physiol. 480:485-92
18. Weinreich D, Wonderlin WF. 1987. Inhibition of calcium-dependent spike after-hyperpolarization increases excitability of rabbit visceral sensory neurons. J. Physiol. 394:415-27
19. + current as a mechanism of primary afferent sensitization. Soc. Neurosci. 21:899
20. Seibert K, Zhinag Y, Leahy K, Hauser S, Masferrer J, et al. 1994. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91:12013-17
21. Boyce S, Chan C, Gordon R, Li C, Rodger IW, et al. 1994. A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulcerations in rats. Neuropharmacology 33:1609-11
22. Lichtenberger LM, Wang Z-M, Romero JJ, Ulloa C, Perez JC, et al. 1995. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med. 1:154-58
23. Kopp E, Ghosh S. 1994. Inhibition of NF-kB by sodium salicilate and aspirin. Science 265:956-59
24. Jurna I, Yaksh TL. 1993. Central mechanisms for analgesia by acetylsalicylic acid and functionally related compounds. Prog. Pharmacol. Clin. Pharmacol. 10:1-122
25. Malmberg AB, Yaksh TL. 1992. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257:1276-79
26. 2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J. Neurosci. 15:2768-76
27. Levine JD, Lam D, Taiwo YO, Donatoni P, Goetzl EJ. 1986. Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proc. Natl. Acad. Sci. USA 83:5331-34
28. 4 induced decrease in mechanical and thermal thresholds of C-fiber mechanociceptors in rat hairy skin. Brain Res. 509:273-79
29. Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R. et al. 1995. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 92: 517-21
30. Dinarello CA. 1992. Role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation. In Inflammation: Basic Principles and Clinical Correlates, ed. JI Gallin, IM Goldstein, N Snyderman, pp. 123-38. New York: Raven. 2nd ed.
31. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. 1988. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334: 698-700
32. Davis AJ, Perkins MN. 1994. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat Br. J. Pharmacol. 113:63-68
33. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. 1991. Interleukin-8 as a mediator of sympathetic pain. Br. J. Pharmacol. 104:765-67
34. Seabrook GR, Bowery BJ, Hill RG. 1995. Bradykinin receptors in mouse and rat isolated superior cervical ganglia. Br. J. Pharmacol. 115:368-72
35. Poole, S, Cunha FQ, Selkirk S, Lorenzetti BB, Ferreira SH. 1995. Cytokine mediated inflammatory hyperalgesia limited by interleukin-10. Br. J. Pharmacol. 115:684-88
36. Jiang C-L, Lu C-L. 1995. Multiple actions of cytokines on the CNS. Trends Neurosci. 18:296
37. Poole S, Bristow AF, Lorenzetti BB, Gaines Das RE, Smith TW, Ferreira SH. 1992. Peripheral analgesic activities of peptides related to α-melanocyte stimulating hormone and interleukuin-1β. Br. J. Pharmacol. 106:489-92
38. Elford PR, Heng R, Revesz L, MacKenzie AR. 1995. Reduction of inflammation and pyrexia in the rai by oral administration of SDZ 224-015, an inhibitor of the interleukin-1β converting enzyme. Br. J. Pharmacol. 115:601-6
39. Lee JC, Laydon JT, McDonnel PC, Gallagher TF, Kumar S, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine synthesis. Nature 372:739-45
40. Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, et al. 1993. Bicyclic imidazolines as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. 696:149-70
41. Dray A, Perkins MN. 1993. Bradykinin and inflammatory pain. Trends Neurosci. 16:99-104
42. Steranka RR, Manning D, DeHass CJ, Ferkany JW, Borosky SA, et al. 1988. Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc. Natl Acad. Sci USA 85:3245-49
43. Heapy CG, Shaw JS, Farmer SC. 1993. Differential sensitivity of antinociceptive assays to the bradykinin antagonist Hoe 140. Br. J. Pharmacol. 108:209-13
44. Perkins MN, Campbell E, Dray A. 1993. Antinociceptive activity of the bradykinin B1 and B 2 receptor antagonists, des-Arg9, (Leu8)-BK and HOE 140, in two models of persistent hyperalgesia in the rat Pain 53:191-97
45. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, et al. Hoe-140 a new potent long acting bradykinin antagonist: in vitro studies. Br. J. Pharmacol. 102:769-74
46. Cheronis JC, Whalley ET, Nguyen KT, Eubanks SR, Allen LG, et al. 1992. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. 35:1563-72
47. Sawutz DG, Salvino JM, Dolle RE, Casiano F, Ward SJ, et al. 1994. The nonpeptide WIN 64388 is a bradykinin B2 receptor antagonist. Proc. Natl. Acad. Sci. USA 91:4693-97
48. Burch RM, Kyle DJ, Stormann TM. 1993. Molecular Biology and Pharmacology of Bradykinin Receptors. Austin, TX: Landes
49. Menke JG, Borkowski JA, Bierilo K, MacNeil T, Derrick AW, et al. 1994. Expression cloning of a human B1 bradykinin receptor. J. Biol. Chem. 269: 21583-86
50. Lewin GR, Mendell LM. 1993. Nerve growth factor and nociception. Trends Neurosci. 16:353-58
51. Wood JN, Lillycrop KA, Dent KL, Ninkana NN, Beech MM, et al. 1992. Regulation of expression of the neuronal POU protein Oct-2 by nerve growth factor. J. Biol. Chem. 267: 17787-91
52. Watson A, Ensor E, Symes A, Winter J, Kendall G, Latchman D. 1995. A minimal CGRP gene promoter is inducible by nerve growth factor in adult rat dorsal root ganglion neurons but not in PC12 phaeochromocytoma cells. Eur. J. Neurosci. 7:394-400
53. Aguayo LG, White G. 1992. Effects of nerve growth factor on TTX- and capsaicin-sensilivity in adult rat sensory neurones. Brain Res. 570:61-67
54. Winter J, Forbes CA, Sterberg J, Lindsay JM. 1988. Nerve growth factor (NGF) regulates adult rat cultured dorsal root ganglion neuron responses to cap-saicin. Neuron 1:973-81
55. Bevan SJ, Geppetti P. 1994. Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci. 17: 509-12
56. Donnerer J, Schuligoi R, Stein C. 1992. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 49:693-98
57. Diamond J, Holmes M, Coughlin M. 1992. Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat. J. Neurosci. 12:1454-66
58. Davis BM, Katz DM, Seroogy KB, Albers KM. 1994. Overexpression of NGF in transgenic mice induces novel sympathetic projections to primary sensory neurons. Soc. Neurosci. Abstr. 20:1090
59. Thompson SWN, Dray A, Urban L. 1995. Nerve growth factor induces mechanical allodynia associated with neurokinin-1 receptor activation and novel A fibre-evoked reflex activity in the rat Pain 62:219-31
60. Woolf CJ, Safieh-Garabedian B, Ma Q-P, Crilly P, Winter J. 1994. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62:327-31
61. Verge VMK, Rishrason PM, Wiesenfeld-Hallin Z, Hokfelt T. 1995. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J. Neurosci. 15: 2081-96
62. Thomas DA, Ren K, Dubner R. 1993. Nerve growth factor alleviates a painfull peripheral neuropathy in rats. Soc. Neurosci. Abstr. 19:969
63. Nowycky M. 1992. Voltage-gated ion channels in dorsal root ganglion neurons. See Ref. 193, pp. 97-115
64. Koerber HR, Mendell LM. 1992. Functional heterogeneity of dorsal root ganglion cells. See Ref. 193, pp. 77-96
65. Rang HP, Bevan SJ, Dray A. 1994. Nociceptive peripheral neurons: cellular properties. See Ref. 1, pp. 57-78
66. Devor M. 1994. The pathophysiology of damaged peripheral nerves. See Ref. 1, pp. 79-100
67. + channels. J. Neurophysiol. 72:349-59
68. Waxman SG, Kocsis JD, Black JA. 1994. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J. Neurophysiol. 72:466-70
69. Marchettini P, Lacerenza M, Marangoni C, Pellegata G, Sotgiu ML, Smirne S. 1992. Lidocaine test in neuralgia. Pain 48:377-82
70. Tanelian DL, Brose WG. 1991. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiology 74:949-51
71. Butterworth JF, Slrichartz GR. 1990. Molecular mechanisms of local anesthesia: a review. Anesthesiology 72:711 -34
72. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol. 40: 756-65
73. Schwarz JR, Grigat G. 1989. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 30:286-94
74. Devor M, Wall PD, Catalan N. 1992. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 48: 261-68
75. Raymond SA, Thalhammer JG, Popitz Bergez F, Strichartz GR. 1990. Changes in axonal impulse conduction correlate with sensory modality in primary afferent fibers in the rat. Brain Res. 526:318-21
76. Devor M, Jänig W, Michælis M. 1994. Modulation of activity in dorsal root ganglion neurons by sympathetic activation in nerve-injured rats. J. Neurophysiol. 71:38-47
77. Kim SH, Chung JM. 1991. Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat. Neurosci. Lett. 134: 131-34
78. Rowbotham MC, Reisner-Keller L, Fields HL. 1991. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41 : 1024-28
79. Xiao W-H, Bennett GJ. 1994. Inhibition of neuropathic pain by N-type calcium channel blockade with omega-conopeptides applied to the site of nerve injury. Soc. Neurosci. Abstr. 20:559
80. Zhang JM, Kitabata LM, LaMotte RH. 1994. Verapamil inhibits the spontaneous activities originating in dorsal root ganglion cells after chronic nerve constriction in rats. Soc. Neurosci. Abstr. 20:760
81. Edwards G, Weston AH. 1993. The pharmacology of ATP-sensitive potassium channels. Annu. Rev. Pharmacol. Toxicol. 33:597-637
82. Naruse K, McGehee DS, Oxford GS. 1992. Differential responses of Ca-activated K channels to bradykinin in sensory neurons and F-11 cells. Am. J. Physiol. 262:C453-60
83. McManus OB, Harris GH, Giangiacomo KM, Feigenbaum P, Reuben JP, et al. 1993. An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry 32:6128-33
84. + channels. Exp. Opin. Invest. Drugs 3:1181-88
85. Ca channel opener, in vascular smooth muscle. Br. J. Pharmacol. 115:1538-47
86. Stretton D, Miura M, Belvisi MG, Barnes PJ. 1992. Calcium-activated potassium channels mediate prejunctional inhibition of peripheral sensory nerves. Proc. Natl. Acad. Sci. USA 89:1325-29
87. Ca channels in acutely dissociated neurones from the rat ventromedial hyzpothalamus by NS 1619. Br. J. Pharmacol. 113:659-61
88. + channels. Br. J. Pharmacol. 115: 381-82
89. Dray A. 1992. Neuropharmacological mechanisms of capsaicin and related substances. Biochem. Pharmacol. 44: 611-15
90. Bevan S, Szolcsanyi J. 1990. Sensory neuron-specific actions of capsaicin: mechanisms and applications. Trend Pharmacol. Sci. 11:330-33
91. Dickenson AH, Dray A. 1991. Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. Br. J. Pharmacol. 104:1045-49
92. Bevan S, Hothi S, Hughes G, James EF, Rang HP, et al. 1995. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br. J. Pharmacol. 197:544-52
93. Campbell EA, Bevan S, Dray A. 1993. Clinical applications of capsaicin and its analogues. In Capsaicin in the Study of Pain, ed. JN Wood, pp. 255-72. London: Academic
94. Hayes AG, Oxford A, Reynolds M, Shingler AH, Skingle M, et al. 1984. The effects of a series of capsaicin analogues on nociception and body temperature in the rat. Life Sci. 34: 1241-48
95. Szolcsanyi J, Jancsó-Gábor A. 1975. Sensory effects of capsaicin congeners. 1. Relationships between chemical structure and pain producing potency of pungent agents. Arzneim. Forsch. Drug Res. 25:1877-81
96. Perkins MN, Campbell EA. 1992 Capsazepine reversal of the analgesic action of capsaicin in vivo. Br. J. Pharmacol. 107:329-33
97. Brand LL, Berman E, Schwen R, Loomans M, Janusz J, et al. 1987. NE-19550: a novel, orally active anti-in flammatory analgesic. Drugs Exp. Clin. Res. 13:259-65
98. Davis KD, Meyer RA, Turnquist JL, Filloon TG, Pappagallo M, Campbell JN. 1995. Cutaneous injection of the capsaicin analogue, NE-21610 produces analgesia to heat but not to mechanical stimuli in man. Pain 61:17-26
99. Walpole CSJ, Wriggiesworth R, Bevan S, Campbell EA, Dray A, et al. 1993. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region." J. Med. Chem. 36:2362-72
100. Walpole CSJ, Wrigglesworth R, Bevan S, Campbell EA, Dray A, et al. 1993. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The amide bond "B-region." J. Med. Chem. 36:2373-80
101. Walpole CSJ, Wrigglesworth R, Bevan S, Campbell EA, Dray A, et al. 1993. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The hydrophobic side-chain "C-region." J. Med. Chem. 36:2381-89
102. Campbell EA, Rang HP, Wrigglesworth R, Walpole CSJ, Bevan S, 1995. The capsaicin analogue, SDZ 249-482, is a potent orally active analgesic in animal models of acute and persistent pain. Am. Pain Soc. In press (Abstr.)
103. Campbell, EA, McMahon SB, Andreev N, Gentry C, Patel S, et al. 1995. The capsaicin analogue, SDZ 249-482, as a topical analgesic in animal models of acute and persistent pain. Am. Pain Soc. In press (Abstr.)
104. Stein C. 1993. Peripheral mechanisms of opioid analgesia. Anesth. Analg. 76: 182-91
105. Schäfer M. Carter L. Stein C. 1994. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc. Natl. Acad. Sci. USA 91: 4219-23
106. Joris J, Costello A, Dubner R, Hargreaves KM. 1990. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain 43:95-103
107. Andreev N, Urban L, Dray A. 1994. Opioids suppress spontaneous activity of polymodal nociceptors in rat paw skin induced by ultraviolet irradiation. Neuroscience 58:793-98
108. Taiwo YO, Levine JD. 1991. Kappa-and delta-opioids block sympathetically dependent hyperalgesia. J. Neurosci. 11: 928-32
109. Shen K-F, Crain SM. 1990. Dynorphin prolongs the action potential of mouse sensory ganglion neurons by decreasing a potassium conductance whereas another specific kappa opioid does so by increasing a calcium conductance. Neuropharmacology 29:343-49
110. Crain SM, Shen K-F. 1990. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11:77-81
111. Nakanishi S. 1991. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14:123-36
112. Maggi CA, Patacchini R, Rovero P, Giachetti A. 1993. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 13:23-93
113. McCarson KE, Krause JE. 1994. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin-induced nociception. J. Neurosci. 14:712-20
114. Krause JE, Blount P, Sachais BS. 1994. Molecular biology of receptors: structure, expression and regulatory mechanisms. In The Tachykinin Receptors, ed. SH Buck, pp. 165-218, Totowa, NJ: Humana
115. Duggan AW, Hendry IA, Morton CR, Hutchison WD, Zhao ZQ. 1988. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res. 451:261-73
116. Go VL, Yaksh TL. 1987. Release of substance P from the cat spinal cord. J. Physiol. 391:141-67
117. Fleetwood-Walker SM, Mitchell R, Hope PJ, El Yassir N, Molony V, Bladon CM. 1990. The involvement of neurokinin receptor subtypes in somatosensory processing in the superficial dorsal horn of the cat. Brain Res. 519: 169-82
118. Nagy I, Maggi CA, Dray A, Woolf CJ, Urban L. 1993. The role of neurokinin and NMDA receptors in capsaicm-sensitive synaptic transmission in the dorsal horn of the rat spinal cord. Neuroscience 52:1029-37
119. Schäfer MK, Nohr D, Krause JE, Weihe E. 1993. Inflammation-induced upregulation of NK1 receptor mRNA in dorsal horn neurones. NeuroReport 4:1007-10
120. Thompson SW, Dray A, Urban L. 1994. Injury-induced plasticity of spinal reflex activity: NK1 neurokinin receptor activation and enhanced A- and C-fiber mediated responses in the rat spinal cord in vitro. J. Neurosci. 14:3672-87
121. Urban L, Thompson SW, Nagy I, Dray A. 1994. Hyperexcitability in the spinal dorsal horn: cooperation of neuropeptides and excitatory amino acids. In Cellular Mechanisms of Sensory Processing, ed. L. Urban, pp. 379-99. Berlin: Springer-Verlag
122. Leslie TA, Emson PC, Dowd PM, Woolf CJ. 1995. Nerve growth factor contributes to the up-regulation of growth associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation. Neuroscience 67: 753-61
123. Liu H, Brown JL, Jasmin L, Maggio JE, Vigna SR, et al. 1994. Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc. Natl. Acad Sci. USA 91:1009-13
124. Valtschanoff JG, Weinberg RJ, Rustioni A. 1995. Central release of tracer after noxious stimulation of the skin suggests non-synaptic signaling by unmyelinated fibres. Neuroscience 64:851-54
125. Urban L, Thompson SWN, Dray A. 1994. Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci. 17:432-38
126. Snider RM, Constantine JW, Lowe JA, Longo KP, Lebel WS, et al. 1991. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251: 435-37
127. Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, et al. 1993. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK-1 antagonist. Eur. J. Pharmacol. 250:403-13
128. Fujii T, Murai M, Morimoto H, Maeda Y, Yamaoka M, et al. 1992. Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br. J. Pharmacol. 107:785-89
129. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, et al. 1991. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. USA 88:10208-12
130. Longmore J, Swain CJ, Hill RG. 1995. Neurokinin receptors. Drug News Perspect. 8:5-22
131. Birch PJ, Harrison SM, Hayes AG, Rogers H, Tyers MB. 1992. The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br. J. Pharmacol. 105:50-10
132. Elliott PJ, Smith GD, Bowers J, Wiseman J, Beresford IJ, Birch PJ. 1993. Antinociceptive effects of the non-peptide NK-1 antagonist (+/-) CP-99,994 in the gerbil. Neuropeptides 24:C15
133. Moussaoui SM, Montier F, Carruette A, Fardin V, Floch A, Garret C. 1994. In vivo pharmacological properties of RPR 100893, a novel non-peptide antagonist of the human NK-1 receptor. Neuropeptides 26(Suppl. 1):C7
134. Yamamoto T, Yaksh TL. 1991. Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. Life Sci. 49:1955-63
135. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. 1994. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 57:153-60
136. Markowitz S, Saito K, Moskowitz MA. 1987. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci. 7:4129-36
137. Moskowitz MA. 1993. Macfarlane R. Neurovascular and molecular mechanisms in migraine headache. Cerebrovasc. Brain Metab. Rev. 5:159-77
138. Walker K, Perkins M, Dray A, 1995. Kinins and kinin receptors in the nervous system. Neurochem. Int. 26:1-16
139. Humphrey PPA, Feniuk W. 1991. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci 12: 444-46
140. Lee WS, Moussaoui SM, Moskowitz MA. 1994. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea pig dura mater and conjunctiva. Br. J. Pharmacol. 112:920-24
141. Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ. 1993. The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br. J. Pharmacol. 108:11-12
142. Moussaoui SM, Philippe L, Le Prado N, Garret C. 1993. Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580. Eur. J. Pharmacol. 238:421-24
143. Brandli P, Loffer B-M, Breu V, Osterwalder R, Maitre J-P, Clozel M, 1995. Role of endothelin in mediating neurogenic plasam extravasation in rat dura mater. Pain. In press
144. Morton CR, Hutchison WD. 1989. Release of sensory neuropeptides in the spinal cord: studies with calcitonin gene-related peptide and galanin. Neuroscience 31:807-15
145. Kuraishj Y, Nanayama T, Ohno H, Minami M, Satoh M. 1988. Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide. Neurosci. Lett. 92:325-29
146. Penn RD, Paice JA, Kroin JS, 1990. Intrathecal octreotide for cancer pain [letter]. Lancet 335:738
147. Schmidt K, Althoff PH, Harris AG, Prestele H, Schumm Draeger PM, Usadel KH. 1993. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up. Pain 53:223-27
148. Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, et al. 1994. Evidence for a long-lasting antinociceptive effect of vapreotide, an analogue of somatostatin, involving an opioidergic mechanism. J. Pharmacol. Exp. Ther. 269: 7-14
149. Bártfai T, Fisone G, Langel U. 1992. Galanin and galanin antagonists. molecular and biochemical perspectives. Trends Pharmacol. Sci. 13:312-17
150. Wiesenfeld-Hallin Z, Xu XJ, Langel U, Bedecs K, Hökfelt T, Bártfai T. 1994. Galanin-mediated control of pain: enhanced role after nerve injury. Proc. Natl. Acad. Sci. USA 89:3334-37
151. Mantyh PW, Allen CJ, Rogers S, DeMaster E, Ghilard JR, et al. 1994. Some sensory neurones express neuropeptide Y receptors: potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injury. J. Neurosci. 14:3958-68
152. Zhang X, Bao L, Xu Z-Q, Kopp J, Arvidsson U, et al. 1994. Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons. Proc Natl. Acad. Sci. USA 91:11738-42
153. Itogawa T, Yamanaka H, Wakisaka S, Sasaki Y, Kato J, et al. 1993. Appearance of neuropeptide-Y like immunoreactivity in the rat trigeminal ganglion following dental injuries. Arch. Oral Biol. 38:725-28
154. Wakisaka S, Kajander KC, Bennett GJ. 1992. Effects of peripheral nerve injuries and tissue inflammation on the levels of neuropeptide Y-like immunoreactivity in rat primary afferent neurons. Brain Res. 598:349-52
155. McLachlan EM, Jänig W, Devor M, Michaelis M. 1993. Peripheral nerve injuries trigger noradrenergic sprouting within dorsal root ganglia. Nature 363: 543-46
156. Colmers WF, Bleakman D. 1994. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17:373-79
157. Baber NS, Dourish CT, Hill DR. 1989. The role of CCK caerulein, and CCK antagonists in nociception. Pain 39: 307-28
158. Stanfa L, Dickenson AH, Xu X, Wiesenfeld-Hallin Z. 1994. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 15:65-66
159. Stanfa LC, Dickenson AH. 1993. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br. J. Pharmacol. 108:967-73
160. Xu X, Hao JX, Seiger A, Hughes J, Hokfelt T, Wiesenfeld-Hallin Z. 1994. Chronic pain-related behaviours in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 56:271-77
161. Woodruff GN, Hughes J. 1991. Cholecystokinin antagonists. Annu. Rev. Pharmacol. Toxicol. 31:469-501
162. Woolf CJ, Doubell TP. 1994. The pathophysiology of chronic pain-increased sensitivity to low threshold Aβ-fibre inputs. Curr. Biol. 4:525-34
163. Haley JE, Sullivan AF, Dickenson AH. 1990. Evidence for spinal N-methyl-D-aspartaie receptor involvement in prolonged chemical nociception in the rat. Brain Res. 518:218-26
164. Woolf CJ, Thompson SW. 1991. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 44:293-99
165. Yaksh TL, Malmberg AB. 1994. Central pharmacology of nociceptive transmission. See Ref. 1, pp. 165-200
166. Kristensen JD, Karlsten R, Gordh T, Berge OG. 1994. The NMDA antagonist 3-(2-carboxypiperazm-4-yl)-propyl-t-phosphonic acid (CPP) has antinociceptive effect after intrathecal injection in the rat. Pain 56:59-67
167. Segum L, Le Marouille-Girardon S, Millan MJ 1995. Antinociceptive profiles of non-peptidergic neurokinin 1 and neurokinin 2 receptor antagonists: a comparison to other classes of anti-nociceptive agents. Pain 61:325-43
168. Kristensen JD, Svensson B, Gordh T, Jr. 1992. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans (see comments). Pain 51:249-53
169. Edwards ND, Fletcher A, Cole JR, Peacock JE. 1993. Combined infusions of morphine and ketamine for postoperative pain in elderly patients. Anaesthesia 48:124-27
170. Hartvig P, Larsson E, Joachimsson PO. 1993. Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. J. Cardiothorac. Vasc. Anesth. 7:148-53
171. Eisenberg E, Vos BP, Strassman AM. 1993. The NMDA antagonist memantine blocks pain behaviour in a rat model of formalin-induced facial pain. Pain 54:301-7
172. Young MR, Fletwood-Walker SM, Mitchell R, Munro FE. 1994. Evidence for a role of metabotropic glutamate receptors in sustained nociceptive inputs to rat dorsal horn neurons. Neuropharmacology 33:141-44
173. Neugebauer V, Lucke T, Scheible H-G. 1994. Requirement of metabotropic glutamate receptor for the generation of inflammation-evoked hyperexcitability in rat spinal cord neurons. Eur. J. Neurosci. 6:1179-86
174. Sylven C. 1989. Angina pectoris. Clinical characteristics, neurophysiological and molecular mechanisms. Pain 36: 145-67
175. Bleehen T, Keele CA. 1977. Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3:367-77
176. Taiwo YO, Levine JD. 1990. Direct cutaneous hyperalgesia induced by adenosine. Neuroscience 38:757-62
177. Sawynok J, Sweeney MI. 1989. The role of purines in nociception. Neuroscience 32:557-69
178. Taiwo YO, Levine JD. 1991. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 44:131-35
179. MacDonald RL, Skerritt JH, Werz MA. 1986. Adenosine agonists reduce voltage dependent calcium conductance of mouse sensory neurones in cell culture. J. Physiol. 370:75-90
180. Sawynok J, Sweeney MI, White TD. 1989. Adenosine release may mediate spinal analgesia by morphine. Trends Pharmacol. Sci. 10:186-89
181. Karlsten R, Gordh T, Post C. 1992. Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosioe analogues in mice. Pharmacol. Toxicol. 70: 434-38
182. Karlstea R, Gordh T Jr, Hartvig P, Post C. 1990. Effects of intrathecal injection of the adenosine receptor agonists R-phenylisopropyl-adenosine and N-ethyl-carboxamide-adenosine on nociception and motor function in the rat. Anesth. Analg. 71:60-64
183. Karlsten R, Post C, Hide I, Daly JW. 1991. The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor. Neurosci Lett. 121:267-70
184. Keil GJ, DeLander GE. 1992. Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci. 51:PL171-76
185. Yaksh TL. 1985. Pharmacology of spinal adrenergjc system which modulates spinal nociceptive processing. Pharmacol. Biochem. Behav. 22:845-58
186. Fisher B, Zornow MH, Yaksh TL, Peterson BM. 1991. Antinociceptive properties of intrathecal dexmedetomidine in rats. Eur. J. Pharmacol. 192:221-25
187. Bonnet F, Boico O, Rostaing S, Loriferne JF, Saada M. 1990. Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. Anesthesiology 72:423-27
188. Eisenach JC, Lysak SZ, Viscomi CM. 1989. Epidural clonidine analgesia during surgery. Anesthesiology 71:640-46
189. Hamon MD, Collin E, Chantrel D, Verge D, Bourgoin S. 1991. The contribution of monoamines and their receptors to pain control. In Towards a New Pharmacotherapy of Pain, ed. AI Basbaum, J Besson, pp. 83-102. Chichester: Wiley
190. Ono H, Mishima A, Ono S, Fukuda H, Vasko MR. 1991. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists. Neuropharmacology 30:585-89
191. Takano Y, Yaksh TL. 1992. Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J. Pharmacol. Exp. Ther. 261:764-72
192. Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JN. 1991. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 47:309-17
193. Collin E, Frechilla D, Pohl M, Bourgoin S, Mauborgne A, Cesselin F. 1994. Differential effects of the novel analgesic, S12813-4, on the spinal release of substance P and calcitonin gene-related peptide-like materials in the rat. Naunym-Schmiedeberg Arch. Pharmacol 349:387-93
194. Scott SA, ed. 1992. Sensory Neurons: Diversity Development and Plasticity. Oxford: Oxford Univ. Press